AP
APNHY.US Aspen Pharmacare Holdings Ltd ADR
- Market cap
- USD 4.58B
- P/E
- -
- P/B
- 0.94x
- ROE
- 3.3%
- Dividend yield
- 1.33%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is APNHY.US undervalued?
Graham numberThe Graham number of Aspen Pharmacare Holdings Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aspen Pharmacare Holdings Ltd ADR fundamental analysis
No fundamental analysis for Aspen Pharmacare Holdings Ltd ADR yet.
Aspen Pharmacare Holdings Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aspen Pharmacare Holdings Ltd ADR
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such…
Full company profileAspen Pharmacare Holdings Ltd ADR financial statements
Aspen Pharmacare Holdings Ltd ADR annual financial statements (ZAR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 41.2B | 42.6B | 38.9B | 38.6B | 37.8B | 38.6B | 40.7B | 44.7B | 43.4B | 34.1B |
| Gross Profit | 19.9B | 21.6B | 19.7B | 19.3B | 17.8B | 18.3B | 18.4B | 19.4B | 19.1B | 13.8B |
| Operating Income | 8.30B | 9.24B | 4.81B | 7.06B | 7.07B | 8.67B | 7.82B | 7.00B | 1.44B | 5.29B |
| EBITDA | 9.50B | 10.1B | 5.65B | 7.32B | 8.68B | 10.5B | 10.7B | 9.91B | 3.62B | 7.16B |
| Net Income | 5.10B | 6.01B | 6.46B | 4.66B | 4.81B | 6.49B | 5.23B | 4.40B | -1.08B | 2.59B |
| EPS | 11 | 13 | 14 | 10 | 11 | 14 | 12 | 9.91 | -2.44 | 5.84 |
| Balance Sheet | ||||||||||
| Total Assets | 116B | 133B | 122B | 133B | 110B | 111B | 134B | 139B | 136B | 107B |
| Total Liabilities | 73.2B | 82.7B | 68.1B | 64.0B | 44.1B | 40.4B | 48.0B | 54.3B | 51.0B | 27.7B |
| Shareholders' Equity | 43.1B | 50.1B | 54.2B | 69.2B | 65.6B | 70.9B | 86.2B | 84.9B | 84.9B | 79.7B |
| Cash & Short-term Investments | 10.7B | 11.2B | 8.98B | 7.09B | 8.55B | 6.18B | 10.9B | 12.3B | 6.41B | 15.9B |
| Total Debt | 47.8B | 58.0B | 48.0B | 42.3B | 24.9B | 22.2B | 29.3B | 36.5B | 36.1B | 15.4B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 6.50B | 7.02B | 6.00B | 8.26B | 6.83B | 5.37B | 5.52B | 6.23B | 5.16B | 6.73B |
| Capital Expenditure | 2.60B | 8.23B | 3.58B | 2.69B | 3.43B | 2.70B | 3.18B | 5.54B | 5.06B | 2.10B |
| Free Cash Flow | 3.90B | -1.21B | 2.42B | 5.57B | 3.39B | 2.68B | 2.34B | 690M | 104M | 4.63B |
| Ratios | ||||||||||
| ROE | 11.8% | 12.0% | 11.9% | 6.7% | 7.3% | 9.1% | 6.1% | 5.2% | -1.3% | 3.3% |
| ROA | 4.4% | 4.5% | 5.3% | 3.5% | 4.4% | 5.8% | 3.9% | 3.2% | -0.8% | 2.4% |
| Net Profit Margin | 12.4% | 14.1% | 16.6% | 12.1% | 12.7% | 16.8% | 12.8% | 9.9% | -2.5% | 7.6% |
| Debt to Equity | 1.11x | 1.16x | 0.88x | 0.61x | 0.38x | 0.31x | 0.34x | 0.43x | 0.43x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aspen Pharmacare Holdings Ltd ADR dividends
- Dividend yield
- 1.33%
- Forward dividend
- 0.14 USD
- Payout ratio
- 35.5%
- Ex-dividend date
- Oct 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | ZAR 921M | 2.07 | 35.5% |
| 2025 | ZAR 1.60B | 3.60 | - |
| 2024 | ZAR 1.53B | 3.43 | 34.6% |
| 2023 | ZAR 1.46B | 3.28 | 27.8% |
| 2022 | ZAR 1.20B | 2.64 | 18.4% |
| 2021 | ZAR 1.20B | 2.62 | 24.9% |
| 2020 | ZAR 1.20B | 2.62 | 25.6% |
| 2019 | ZAR 1.44B | 3.15 | 22.2% |
| 2018 | ZAR 1.31B | 2.88 | 21.8% |
| 2017 | ZAR 1.20B | 2.63 | 23.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Jul 18, 2012.
Who owns Aspen Pharmacare Holdings Ltd ADR
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 433M
- Free float 364M
Aspen Pharmacare Holdings Ltd ADR company profile
- Company name
- Aspen Pharmacare Holdings Ltd ADR
- Ticker
- APNHY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,283
- Fiscal year end
- June
- Address
- Aspen Place, Durban, South Africa
- Phone
- 27 31 580 8600
- Website
- aspenpharma.com
About Aspen Pharmacare Holdings Ltd ADR
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Sandostatin, Sustanon, and Xylocaine brands. It also provides over-the-counter topical products through retail pharmacy and fast-moving consumer goods sectors under the EMLA, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for therapeutic areas, including anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Meticorten brands. In addition, the company manufactures active pharmaceutical ingredients; finished dose form products manufactured for third parties; and heparin-based API to third parties. Further, it exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Aspen Pharmacare Holdings Ltd ADR management
7- Mr. Stephen Bradley Saad BCom, CA(SA)Group CEO & Executive Director · born 1964
- Mr. Sean M. CapazorioGroup CFO & Executive Director · born 1967
- Ms. Lorraine HillGroup Chief Operations Officer · born 1964
- Mr. Michael Guy Attridge B.Com., CA(SA)Group Chief Advisor · born 1961
- Mr. Reginald Haman Grad. Dip., MBA, ND, NHD, PGDBAConsultant · born 1975
- Ms. Raeesa KhanGroup Company Secretary & Chief of Staff · born 1991
- Mr. Samer KassemChief Executive Officer of Aspen Global Incorporated · born 1975